Table 2.

In vivo experimental data of radiosensitization effects

Authors	CDK4/6 inhibitor	Xenograft	Efficacy with radiotherapy
Hashizume et al. [42]	Palbociclib	Intracranial ATRT (BT12) (BT16) Glioblastoma (GBM43)	Median survival time increased by 24 to 26 days (1.4-fold) Median survival time increased by 31.5 to 34.5 days (3.3-fold) Median survival time increased by 10 to 13.5 days (1.6-fold)
Whittaker et al. [43]	Palbociclib	Glioblastoma (RN1)	Median survival time increased by 8 days
Naz et al. [44]	Abemaciclib	NSCLC (H460)	Tumor regrowth delay 8 and 9 days, inhibit IR-induced tumor vasculogenesis
Tao et al. [30]	Palbociclib and Trametinib	NSCLC (A549)	Tumor volume ↓ Proliferation ↓ Apoptosis ↑
Huang et al. [45]	Palbociclib	HCC (Huh7)	Tumor volume ↓ Tumor weight ↓
Li et al. [50]	Ribociclib and CA3	EAC (Flo-1 XTR)	Tumor volume ↓ Tumor weight ↓
Barton et al. [52]	Palbociclib	Ink4a-ARF- deficient BSG a mouse model	Median survival time increased by 10 days (19%)

^a BSG, brainstem glioma